10. Cancelled.

11. (Original) The compound of claim 1, wherein the compound comprises 3-(4-Benzyloxyphenyl)propionic Acid 2,4-Di-(3-Diethylamino-1-propoxy)aniline Amide.

12. (Amended) The compound of claim ~~1~~ 62, wherein the compound comprises 3-(3-Tert-butoxyphenyl)-3-(9-fluorenylmethoxycarbonylamino)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide.

A1

13. (Amended) The compound of claim ~~1~~ 62, wherein the compound comprises 3-(3-Tert-butoxyphenyl)-3-aminopropionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide.

14. (Original) The compound of claim 1, wherein the compound comprises 3-(4-Tetrahydropyranyl)-2-aminopropionic Acid 4-Diethylaminoethoxycarbonyl-2-butoxyaniline Amide Dihydrochloride.

15. (Original) The compound of claim 1, wherein the compound comprises (2S, 4R)-4-Tert-Butoxypyrrolidine-2-carboxylic acid 2,4-Di(3-diethylamino-1-propoxy)aniline Amide.

16. (Original) The compound of claim 1, wherein the compound comprises (3S)-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid 4-Diethylaminoethoxycarbonyl-2-butoxyaniline Amide Dihydrochloride.

17. (Original) The compound of claim 1, wherein the compound comprises (R)-3-(4-Benzyloxyphenyl)-2-(1-imidazolyl)propionic Acid 4-Diethylaminoethoxycarbonyl-2-butoxyaniline Amide.

18. (Amended) The compound of claim ~~1~~ 62, wherein the compound comprises 3-(4-Tert-butoxyphenyl)-3-(9-fluorenylmethoxycarbonylamino)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide.

19. (Amended) The compound of claim ~~1~~ 62, wherein the compound comprises 3-amino-3-(4-tert-butoxyphenyl)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide.

A2

20. (Amended) The compound of claim ~~1~~ 62, wherein the compound comprises 3-(9-fluorenylmethoxycarbonylamino)-3-(2-tert-butoxyphenyl)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide.

A2 cont.

21. (Amended) The compound of claim ~~1~~ 62, wherein the compound comprises 3-amino-3-(2-tert-butoxyphenyl)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide.

22. (Amended) The compound of claim ~~1~~ 62, wherein the compound comprises 3-Isopropylamino-3-(3-tert-butoxyphenyl)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide.

---

23. (Original) The compound of claim 1, wherein the compound comprises (2R)-2-tert-butoxycarbonylamino-3-[4-(benzyloxy)phenyl]propionic Acid 4-(3-diethylaminopropoxy)-N-benzylaniline Amide.

24. (Original) The compound of claim 1, wherein the compound comprises (2R)-2-tert-butoxycarbonylamino-3-[4-(benzyloxy)phenyl]propionic Acid 4-(3-diethylaminopropoxy)-N-cyclopentylmethylaniline Amide.

25. (Original) The compound of claim 1, wherein the compound comprises (2R)-2-tert-butoxycarbonylamino-3-[4-(benzyloxy)phenyl]propionic Acid 4-(3-diethylaminopropoxy)-N-isopropylaniline Amide.

26. (Original) The compound of claim 1, wherein the compound comprises (2R)-2-amino-3-[4-(benzyloxy)phenyl]propionic Acid 4-(3-diethylaminopropoxy)-N-cyclohexylmethylaniline Amide.

27. (Original) The compound of claim 1, wherein the compound comprises (2R)-2-amino-3-[4-(benzyloxy)phenyl]propionic Acid 4-(3-diethylaminopropoxy)-N-cyclopentylmethylaniline Amide.

28. (Original) The compound of claim 1, wherein the compound comprises (2R)-2-tert-butoxycarbonylamino-3-[4-(benzyloxy)phenyl]propionic Acid 4-(3-diethylaminopropoxy)-N-butylaniline Amide.

29. (Original) The compound of claim 1, wherein the compound comprises (2R)-2-amino-3-[4-(benzyloxy)phenyl]propionic Acid 4-(3-diethylaminopropoxy)-N- butylaniline Amide.

30. (Original) The compound of claim 1, wherein the compound comprises (2R)-2-tert-butoxycarbonylamino-3-[4-(benzyloxy)phenyl]propionic Acid 3-(3-diethylaminopropoxy)-N-butylaniline Amide.

31. (Original) The compound of claim 1, wherein the compound comprises (2R)-2-amino-3-[4-(benzyloxy)phenyl]propionic Acid 3-(3-diethylaminopropoxy)-N- butylaniline Amide.

32. (Original) The compound of claim 1, wherein the compound comprises 3-(1-Tert-butoxycarbonylpiperidin-4-yl)-2-(9-fluorenylmethoxycarbonylamino)propionic Acid 4-Diethylaminopropoxy-2-butoxyaniline Amide.

33. (Original) The compound of claim 1, wherein the compound comprises 3-(Piperidin-4-yl)-2-(9-fluorenylmethoxycarbonylamino)propionic Acid 4-Diethylaminopropoxy-2-butoxyaniline Amide.

34. (Original) The compound of claim 1, wherein the compound comprises 3-(1-Benzylpiperidin-4-yl)-2-(9-fluorenylmethoxycarbonylamino)propionic Acid 4-Diethylaminopropoxy-2-butoxyaniline Amide.

35. (Original) The compound of claim 1, wherein the compound comprises 3-(1-Benzylpiperidin-4-yl)-2-aminopropionic Acid 4-Diethylaminopropoxy-2-butoxyaniline Amide.

36. (Original) The compound of claim 1, wherein the compound comprises 3-(1-Benzyloxycarbonylpiperidin-4-yl)-2-(9-fluorenylmethoxycarbonyamino)propionic Acid 4-Diethylaminopropoxy-2-butoxyaniline Amide.

37. (Original) The compound of claim 1, wherein the compound comprises 3-(1-Benzoylpiperidin-4-yl)-2-(9-fluorenylmethoxycarbonylamino)propionic Acid 4-Diethylaminopropoxy-2-butoxyaniline Amide.

38. (Original) The compound of claim 1, wherein the compound comprises 3-(1-Benzoylpiperidin-4-yl)-2-benzoylaminopropionic Acid 4-Diethylaminopropoxy-2-butoxyaniline Amide.

39. (Original) The compound of claim 1, wherein the compound comprises 3-(Tert-butoxycarbonylpiperidin-3-yl)-2-(9-fluorenylmethoxycarbonylamino)propionic Acid 4-Diethylaminopropoxy-2-butoxyaniline Amide.

40. (Original) The compound of claim 1, wherein the compound comprises 3-(Piperidin-3-yl)-2-(9-fluorenylmethoxycarbonylamino)propionic Acid 4-Diethylaminopropoxy-2-butoxyaniline Amide.

41. (Original) A pharmaceutical composition comprising the compound of Formula (I) as claimed in claim 1, and one or more pharmaceutically acceptable carriers, excipients, or diluents.

42. (Original) The pharmaceutical composition of claim 41, in the form of an oral dosage or parenteral dosage unit.

43. (Original) The pharmaceutical composition of claim 41, wherein said compound is administered as a dose in a range from about 0.01 to 500 mg/kg of body weight per day.

44. (Original) The pharmaceutical composition of claim 41, wherein said compound is administered as a dose in a range from about 0.1 to 200 mg/kg of body weight per day.

45. (Original) The pharmaceutical composition of claim 41, wherein said compound is administered as a dose in a range from about 0.1 to 100 mg/kg of body weight per day.

46. (Original) The pharmaceutical composition of claim 41, further comprising one or more therapeutic agents selected from the group consisting of alkylating agents, antimetabolites, plant alkaloids, antibiotics, hormones, biologic response modifiers, analgesics, NSAIDs, DMARDs, glucocorticoids, sulfonylureas, biguanides, insulin, cholinesterase inhibitors, antipsychotics, antidepressants, and anticonvulsants.

47. (Original) A method for the inhibition of the interaction of RAGE with its physiological ligands, which comprises administering to a subject in need thereof, at least one compound of Formula (I) as claimed in claim 1.

48. (Original) The method of claim 47, wherein the ligand(s) is(are) selected from advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin.

49. (Original) A method for treating a disease state selected from the group consisting of acute and chronic inflammation, symptoms of diabetes, vascular permeability, nephropathy, atherosclerosis, retinopathy, Alzheimer's disease, erectile dysfunction, and tumor invasion and/or metastasis, which comprises administering to a subject in need thereof a therapeutically effective amount of at least one compound of Formula (I) as claimed in claim 1.

50. (Original) A method of prevention and/or treatment of RAGE mediated human diseases comprising administration to a human in need thereof a therapeutically effective amount of a compound of Formula (I) as claimed in claim 1, wherein a therapeutically effective amount comprises sufficient compound to at least partially inhibit the binding of a ligand to the RAGE receptor.

51. (Original) The method of claim 50, further comprising administering to a subject in need thereof at least one adjuvant and/or additional therapeutic agent(s).

52. (Original) A method of claim 51, wherein therapeutic agents selected from the group consisting of alkylating agents, antimetabolites, plant alkaloids, antibiotics, hormones, biologic response modifiers, analgesics, NSAIDs, DMARDs, glucocorticoids, sulfonylureas, biguanides, insulin, cholinesterase inhibitors, antipsychotics, antidepressants, and anticonvulsants.

53. (Original) The method claim 50, wherein the RAGE mediated human disease comprises acute and/or chronic inflammation.

54. (Original) The method claim 50, wherein the RAGE mediated human disease comprising vascular permeability.

55. (Original) The method claim 50, wherein the RAGE mediated human disease comprising ephropathy.

56. (Original) The method claim 50, wherein the RAGE mediated human disease comprising atherosclerosis.

57. (Original) The method claim 50, wherein the RAGE mediated human disease comprising retinopathy.

58. (Original) The method claim 50, wherein the RAGE mediated human disease comprising Alzheimer's disease.

59. (Original) The method claim 50, wherein the RAGE mediated human disease comprises erectile dysfunction.

60. (Original) The method claim 50, wherein the RAGE mediated human disease comprises tumor invasion and/or metastasis.

---

61. (New) The compound of claim 1, wherein

G_1 comprises $-CH_2-$

G_2 comprises

A3



wherein

R_5 comprises –H; and

R_6 comprises

i) –H;

ii) $-C_{1-6}$ alkyl;

iii) –aryl;

iv) -C_{1-6} alkylaryl;

v) -C(O)-O-C_{1-6} alkyl;

vi) -C(O)-O-C_{1-6} alkylaryl;

vii) -C(O)-O-C_{1-6} alkylcycloalkylaryl;

viii) -C(O)-NH-C_{1-6} alkyl;

ix) -C(O)-NH-C_{1-6} alkylaryl;

x) -SO_2-C_{1-6} alkyl;

xi) -SO_2-C_{1-6} alkylaryl;

xii) -SO_2-aryl;

xiii) -SO_2-NH-C_{1-6} alkyl;

xiv) -SO_2-NH-C_{1-6} alkylaryl;

A3 cont.

xv) 

;

xvi) -C(O)-C_{1-6} alkyl; or

xvii) -C(O)-C_{1-6} alkylaryl;

R_1 comprises –H;

R_2 comprises

a) -C_{1-6} alkyl;

b) –aryl;

c) -C_{1-6} alkylaryl; or

d) a group of the formula



wherein m and n are independently selected from 1, 2, 3, or 4; X comprises a direct bond, CH_2-, -O-, -S-, -S(O_2)-, -C(O)-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -$NHSO_2$-, -SO_2N(H)-, -C(O)-O-, -O-C(O)-, -$NHSO_2NH$-,



$-Q_1-$ comprises C_{1-6} alkylene, C_{2-6} alkenylene, or C_{2-6} alkynylene;

R_3 comprises –H; and

R_4 comprises

a)



b)



; and

c)



wherein L comprises -CH_2-, -O-, -N(H)-, -S-, SO_2-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -$NHSO_2$-, -SO_2N(H)-, -C(O)-O-, -$NHSO_2NH$-, -O-CO-,



R_{36} and R_{37} independently comprise hydrogen, aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, or C_1-C_6 alkoxyaryl;

R_7, R_8, R_{12} and R_{13} independently comprise hydrogen, C_1-C_6 alkyl, C_1-C_6 alkylaryl, or aryl; and wherein

the aryl and/or alkyl group(s) in R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_{12} and R_{13} may be optionally substituted 1-4 times with a substituent group, wherein said substituent group(s) or the term substituted refers to groups comprising:

a) -H;

b) -Y-C_{1-6} alkyl;
-Y-aryl;
-Y-C_{-1-6} alkylaryl;
-Y-C_{1-6}-alkyl-$NR_{14}R_{15}$;
-Y-C_{1-6}-alkyl-W-R_{16};

A3 Cont

wherein Y and W independently comprise -CH_2-, -O-, -N(H), -S-, SO_2-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -$NHSO_2$-, -SO_2N(H)-, -C(O)-O-, -$NHSO_2$NH-, -O-CO-,



R_{16}, R_{17}, and R_{18} comprise hydrogen, aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, or C_1-C_6 alkoxyaryl; or

c) halogen, hydroxyl, cyano, carbamoyl, or carboxyl; and

R_{14} and R_{15} independently comprise hydrogen, aryl, C_1-C_6 alkyl, or C_1-C_6 alkylaryl; and wherein

R_{14} and R_{15} may be taken together to form a ring having the formula -$(CH_2)_o$-Z-$(CH_2)_p$- bonded to the nitrogen atom to which R_{14} and R_{15} are attached, and/or R_7 and R_8 may, independently,

be taken together to form a ring having the formula $-(CH_2)_o-Z-(CH_2)_p-$ bonded to the atoms to which R_7 and R_8 are attached, wherein o and p are, independently, 1, 2, 3, or 4; Z comprises a direct bond, $-CH_2-$, -O-, -S-, $-S(O_2)-$, -C(O)-, -CON(H)-, -NHC(O)-, -NHCON(H)-, $-NHSO_2-$, $-SO_2N(H)-$, -C(O)-O-, -O-C(O)-, $-NHSO_2NH-$,



R_{19} and R_{20} independently comprise hydrogen, aryl, C_1-C_6 alkyl, or C_1-C_6 alkylaryl.

62. (New) The compound of claim 61,

wherein

G_1 comprises $-CH_2-$

G_2 comprises



wherein

R_5 comprises –H; and

R_6 comprises

i) –H;

ii) $-C_{1-6}$ alkyl; or

iii) $-C(O)-O-C_{1-6}$ alkylcycloalkylaryl;

R_1 comprises –H;

R_2 comprises



;

R_3 comprises –H; and

R_4 comprises

a)



;

b)



; and

c)



;

wherein L comprises -CH_2-, -O-, -N(H)-, -S-, SO_2-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -$NHSO_2$-, -SO_2N(H)-, -C(O)-O-, -$NHSO_2$NH-, -O-CO-,



;

R_{36} and R_{37} independently comprise hydrogen, aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, or C_1-C_6 alkoxyaryl;

R_7, R_8, R_{12} and R_{13} independently comprise hydrogen, C_1-C_6 alkyl, C_1-C_6 alkylaryl, or aryl; and wherein

the aryl and/or alkyl group(s) in R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_{12} and R_{13} may be optionally substituted 1-4 times with a substituent group, wherein said substituent group(s) or the term substituted refers to groups comprising:

a) -H;

b) -Y-C_{1-6} alkyl;
-Y-aryl;
-Y-C_{-1-6} alkylaryl;
-Y-C_{1-6}-alkyl-$NR_{14}R_{15}$;
-Y-C_{1-6}-alkyl-W-R_{16};

wherein Y and W independently comprise -CH_2-, -O-, -N(H), -S-, SO_2-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -$NHSO_2$-, -$SO_2N(H)$-, -C(O)-O-, -$NHSO_2NH$-, -O-CO-,



R_{16}, R_{17}, and R_{18} comprise hydrogen, aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, or C_1-C_6 alkoxyaryl; or

c) halogen, hydroxyl, cyano, carbamoyl, or carboxyl; and

R_{14} and R_{15} independently comprise hydrogen, aryl, C_1-C_6 alkyl, or C_1-C_6 alkylaryl; and wherein

R_{14} and R_{15} may be taken together to form a ring having the formula -$(CH_2)_o$-Z-$(CH_2)_p$- bonded to the nitrogen atom to which R_{14} and R_{15} are attached, and/or R_7 and R_8 may, independently, be taken together to form a ring having the formula -$(CH_2)_o$-Z-$(CH_2)_p$- bonded to the atoms to which R_7 and R_8 are attached, wherein o and p are, independently, 1, 2, 3, or 4; Z comprises a direct bond, -CH_2-, -O-, -S-, -$S(O_2)$-, -C(O)-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -$NHSO_2$-, -$SO_2N(H)$-, -C(O)-O-, -O-C(O)-, -$NHSO_2NH$-,

A3 cont.



R_{19} and R_{20} independently comprise hydrogen, aryl, C_1-C_6 alkyl, or C_1-C_6 alkylaryl.